Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (NYSE:PFE) from Buy to Neutral. Analyst Price Forecast Suggests 39.12% Upside As of April 1, 2025 ...

Pfizer ( ($PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Pfizer (PFE) has been the focus of ...

Goldman Sachs downgraded Pfizer (PFE) to Neutral from Buy with a price target of $25, down from $32, after assuming coverage of the name. The firm says that on the back of a challenging past two ...

In today’s CEO Daily: Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

Wall Street’s top firms have been reluctant to criticize President Trump’s trade policy, but Goldman took it to a new level ...

BMY), Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV). Eli Lilly (LLY) has ended a three-day selloff after Goldman Sachs analyst Asad Haider upgraded the Indiana-based drugmaker to Buy from Neutral ...

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (SNSE:PFE) from Buy to Neutral. There are 4,005 funds or institutions reporting positions in Pfizer.